BR9610511B1 - construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica. - Google Patents
construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.Info
- Publication number
- BR9610511B1 BR9610511B1 BRPI9610511-9A BR9610511A BR9610511B1 BR 9610511 B1 BR9610511 B1 BR 9610511B1 BR 9610511 A BR9610511 A BR 9610511A BR 9610511 B1 BR9610511 B1 BR 9610511B1
- Authority
- BR
- Brazil
- Prior art keywords
- interest
- gene therapy
- pharmaceutical composition
- dna constructs
- nucleic sequence
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000010076 replication Effects 0.000 abstract 2
- 108020004638 Circular DNA Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 241001515965 unidentified phage Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9510825A FR2738842B1 (fr) | 1995-09-15 | 1995-09-15 | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
PCT/FR1996/001414 WO1997010343A1 (fr) | 1995-09-15 | 1996-09-13 | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
Publications (3)
Publication Number | Publication Date |
---|---|
BR9610511A BR9610511A (pt) | 1999-01-26 |
BR9610511B1 true BR9610511B1 (pt) | 2010-10-19 |
BRPI9610511B8 BRPI9610511B8 (pt) | 2016-11-08 |
Family
ID=9482580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9610511A BRPI9610511B8 (pt) | 1995-09-15 | 1996-09-13 | construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica. |
Country Status (20)
Country | Link |
---|---|
US (3) | US6977174B2 (pt) |
EP (3) | EP1724354B1 (pt) |
JP (3) | JP3818665B2 (pt) |
KR (1) | KR100522369B1 (pt) |
AT (3) | ATE492642T1 (pt) |
BR (1) | BRPI9610511B8 (pt) |
CA (1) | CA2229307C (pt) |
CZ (1) | CZ294525B6 (pt) |
DE (3) | DE69636878T2 (pt) |
DK (3) | DK1724354T3 (pt) |
ES (3) | ES2357098T3 (pt) |
FR (1) | FR2738842B1 (pt) |
HU (1) | HU224400B1 (pt) |
IL (4) | IL123641A0 (pt) |
NO (1) | NO323975B1 (pt) |
PT (3) | PT850310E (pt) |
SK (1) | SK285317B6 (pt) |
TW (1) | TWI231826B (pt) |
WO (1) | WO1997010343A1 (pt) |
ZA (1) | ZA967640B (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7038026B2 (en) * | 2000-05-26 | 2006-05-02 | Centelion | Purification of a triple heli formation with an immobilized oligonucleotide |
US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
US6156574A (en) | 1997-06-23 | 2000-12-05 | The Rockefeller University | Methods of performing gene trapping in bacterial and bacteriophage-derived artificial chromosomes and use thereof |
US6821759B1 (en) | 1997-06-23 | 2004-11-23 | The Rockefeller University | Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof |
AU8444798A (en) | 1997-06-30 | 1999-01-25 | Centre National De La Recherche Scientifique | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
US6022716A (en) * | 1998-04-10 | 2000-02-08 | Genset Sa | High throughput DNA sequencing vector |
WO2000075299A1 (en) * | 1999-06-07 | 2000-12-14 | Cell Genesys, Inc. | Hybrid yeast-bacteria cloning system and uses thereof |
AU6229800A (en) * | 1999-07-20 | 2001-02-05 | Rockefeller University, The | Conditional homologous recombination of large genomic vector inserts |
FR2821855B1 (fr) † | 2001-03-09 | 2004-04-02 | Cayla | Genes synthetiques et plasmides bacteriens depourvus de cpg |
FR2822476B1 (fr) * | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice |
WO2003004088A2 (en) | 2001-07-05 | 2003-01-16 | Aventis Pharma S.A. | Method of administration of a gene of interest to the heart and vasculature |
US6989261B2 (en) | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
US7049121B2 (en) | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
FI116068B (fi) | 2003-09-15 | 2005-09-15 | Fit Biotech Oyj Plc | Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi |
JP4581851B2 (ja) * | 2004-07-27 | 2010-11-17 | セイコーエプソン株式会社 | 電気光学装置の駆動回路及び駆動方法、電気光学装置並びに電子機器 |
AU2006246975B2 (en) * | 2005-05-17 | 2011-08-11 | Ozgene Pty Ltd | Sequential cloning system |
WO2007030588A1 (en) * | 2005-09-07 | 2007-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of replicators to prevent gene silencing |
EP1943265B1 (en) * | 2005-10-01 | 2012-09-12 | Charles Stout | Regulatable fusion promoters |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
JP5774480B2 (ja) * | 2008-07-18 | 2015-09-09 | マックスサイト インコーポレーティッド | 電気穿孔を最適化するための方法 |
EP2221066A1 (en) | 2009-02-18 | 2010-08-25 | Sanofi-Aventis | Use of VgII3 activity modulator for the modulation of adipogenesis |
ES2566553T3 (es) | 2010-03-17 | 2016-04-13 | Association Institut De Myologie | ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares |
EP2643343A1 (en) | 2010-11-26 | 2013-10-02 | Institut Pasteur | Identification of a human gyrovirus and applications. |
WO2013083753A2 (en) | 2011-12-07 | 2013-06-13 | Institut Pasteur | Identification of a swine parecho-like virus and applications |
CA2883227A1 (en) | 2012-08-29 | 2014-03-06 | Nature Technology Corporation | Dna plasmids with improved expression |
US20150322439A1 (en) | 2012-11-19 | 2015-11-12 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
AU2014236208B2 (en) * | 2013-03-14 | 2018-07-19 | Genvivo, Inc. | Thymidine kinase diagnostic assay for gene therapy applications |
WO2019057774A1 (en) | 2017-09-19 | 2019-03-28 | Deutsches Krebsforschungszentrum | NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS |
ES2821655T5 (es) | 2017-09-19 | 2024-08-06 | Deutsches Krebsforsch | Vectores de ADN no integrantes para la modificación genética de células |
WO2019183248A1 (en) | 2018-03-21 | 2019-09-26 | Nature Technology Corporation | Viral and non-viral nanoplasmid vectors with improved production |
WO2023241567A1 (zh) * | 2022-06-13 | 2023-12-21 | 南京金斯瑞生物科技有限公司 | 一种可提高无筛选标签质粒制备效率的野生型-突变体π蛋白切换表达系统 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190495A (en) * | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
US4727028A (en) * | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
US4654307A (en) * | 1983-02-17 | 1987-03-31 | The Research Foundation Of State University Of New York | Novel bacteria containing a plasmid having a tRNA code |
US4761367A (en) * | 1984-11-07 | 1988-08-02 | The University Of North Carolina At Chapel Hill | Vectors suitable for detection of eukaryotic DNA regulatory sequences |
US5859208A (en) * | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
US5198343A (en) * | 1986-08-05 | 1993-03-30 | Transgene, S.A. | Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained |
US5591632A (en) * | 1987-03-02 | 1997-01-07 | Beth Israel Hospital | Recombinant BCG |
US5510099A (en) * | 1987-05-01 | 1996-04-23 | Stratagene | Mutagenesis testing using transgenic non-human animals carrying test DNA sequences |
US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
EP0416505A3 (en) * | 1989-09-04 | 1991-10-02 | Takeda Chemical Industries, Ltd. | Expression plasmids and use thereof |
EP0485701A1 (en) * | 1990-09-28 | 1992-05-20 | American Cyanamid Company | Insertion of DNA by modified transposons |
TW201794B (pt) * | 1991-05-03 | 1993-03-11 | American Cyanamid Co | |
US5714323A (en) * | 1991-08-30 | 1998-02-03 | The University Of Medecine And Dentistry Of New Jersey | Over expression of single-stranded molecules |
US5444149A (en) * | 1992-05-11 | 1995-08-22 | Duke University | Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation |
US5434065A (en) * | 1993-05-06 | 1995-07-18 | President And Fellows Of Harvard College | In vivo selection of microbial virulence genes |
ATE218893T1 (de) * | 1993-08-12 | 2002-06-15 | Neurotech Sa | Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten |
US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5700657A (en) * | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
IL109558A (en) * | 1994-05-04 | 2004-08-31 | Yissum Res Dev Co | DNA structures Derived from the SV40 virus that include DNA sequences External |
EP0770130A1 (en) * | 1994-07-08 | 1997-05-02 | Schering Corporation | METHOD FOR IDENTIFYING NUCLEIC ACIDS ENCODING c-fos PROMOTER ACTIVATING PROTEINS |
DE4428402A1 (de) * | 1994-08-11 | 1996-02-15 | Boehringer Mannheim Gmbh | Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen |
US5792647A (en) * | 1995-02-13 | 1998-08-11 | The Johns Hopkins University | Bacterial catabolism of chitin |
US6254874B1 (en) * | 1995-04-13 | 2001-07-03 | President And Fellows Of Harvard College | Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same |
US5763270A (en) * | 1995-06-07 | 1998-06-09 | Genemedicine, Inc. | Plasmid for delivery of nucleic acids to cells and methods of use |
US7364894B2 (en) * | 1995-09-15 | 2008-04-29 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US5851808A (en) * | 1997-02-28 | 1998-12-22 | Baylor College Of Medicine | Rapid subcloning using site-specific recombination |
US5874259A (en) * | 1997-11-21 | 1999-02-23 | Wisconsin Alumni Research Foundation | Conditionally amplifiable BAC vector |
-
1995
- 1995-09-15 FR FR9510825A patent/FR2738842B1/fr not_active Expired - Lifetime
-
1996
- 1996-09-10 ZA ZA967640A patent/ZA967640B/xx unknown
- 1996-09-13 AT AT06017245T patent/ATE492642T1/de active
- 1996-09-13 IL IL12364196A patent/IL123641A0/xx active IP Right Grant
- 1996-09-13 PT PT96931124T patent/PT850310E/pt unknown
- 1996-09-13 DE DE69636878T patent/DE69636878T2/de not_active Expired - Lifetime
- 1996-09-13 EP EP06017245A patent/EP1724354B1/fr not_active Expired - Lifetime
- 1996-09-13 DE DE69634043T patent/DE69634043T2/de not_active Expired - Lifetime
- 1996-09-13 PT PT06017245T patent/PT1724354E/pt unknown
- 1996-09-13 AT AT04016978T patent/ATE352630T1/de active
- 1996-09-13 ES ES06017245T patent/ES2357098T3/es not_active Expired - Lifetime
- 1996-09-13 BR BRPI9610511A patent/BRPI9610511B8/pt active IP Right Grant
- 1996-09-13 HU HU9900018A patent/HU224400B1/hu not_active IP Right Cessation
- 1996-09-13 AT AT96931124T patent/ATE284966T1/de active
- 1996-09-13 DK DK06017245.9T patent/DK1724354T3/da active
- 1996-09-13 WO PCT/FR1996/001414 patent/WO1997010343A1/fr active Application Filing
- 1996-09-13 CA CA2229307A patent/CA2229307C/fr not_active Expired - Fee Related
- 1996-09-13 ES ES04016978T patent/ES2281721T3/es not_active Expired - Lifetime
- 1996-09-13 EP EP04016978A patent/EP1508620B1/fr not_active Expired - Lifetime
- 1996-09-13 DK DK96931124T patent/DK0850310T3/da active
- 1996-09-13 EP EP96931124A patent/EP0850310B1/fr not_active Expired - Lifetime
- 1996-09-13 KR KR1019980701938A patent/KR100522369B1/ko not_active IP Right Cessation
- 1996-09-13 SK SK347-98A patent/SK285317B6/sk not_active IP Right Cessation
- 1996-09-13 ES ES96931124T patent/ES2233975T3/es not_active Expired - Lifetime
- 1996-09-13 JP JP51171697A patent/JP3818665B2/ja not_active Expired - Fee Related
- 1996-09-13 US US09/043,193 patent/US6977174B2/en not_active Expired - Lifetime
- 1996-09-13 DK DK04016978T patent/DK1508620T3/da active
- 1996-09-13 DE DE69638314T patent/DE69638314D1/de not_active Expired - Lifetime
- 1996-09-13 CZ CZ1998788A patent/CZ294525B6/cs not_active IP Right Cessation
- 1996-09-13 PT PT04016978T patent/PT1508620E/pt unknown
- 1996-09-14 TW TW090120803A patent/TWI231826B/zh not_active IP Right Cessation
-
1998
- 1998-03-10 NO NO19981044A patent/NO323975B1/no not_active IP Right Cessation
- 1998-03-11 IL IL123641A patent/IL123641A/en not_active IP Right Cessation
-
2005
- 2005-12-02 JP JP2005348779A patent/JP4585435B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-26 IL IL173399A patent/IL173399A/en not_active IP Right Cessation
-
2007
- 2007-08-07 JP JP2007205143A patent/JP4756014B2/ja not_active Expired - Fee Related
- 2007-10-30 US US11/978,614 patent/US20090130674A1/en not_active Abandoned
-
2008
- 2008-05-27 US US12/153,881 patent/US20090149406A1/en not_active Abandoned
-
2010
- 2010-08-02 IL IL207348A patent/IL207348A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9610511B1 (pt) | construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica. | |
WO1996021007A3 (en) | Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells | |
DE69637147D1 (de) | Transportproteine und deren verwendungen | |
BR9607273A (pt) | Molécula de dna duplo filamento dna recombinante plasmídio célula recombinante composiçao farmacéutica e processo de preparaçao de uma molécula de dna | |
DK1394179T3 (da) | Fremgangsmåde til fremstilling af erythropoietin fri for animalske proteiner | |
SG141233A1 (en) | Control of gene expression | |
DK1783225T3 (da) | Strukturprotein fra AAV, dets fremstilling og anvendelse | |
NO176921C (no) | Genteknologisk fremgangsmåte for fremstilling av et tPA-lignende protein, samt vertscelle som er i stand til å uttrykke et slikt protein | |
AU2434195A (en) | Thymidine kinase mutants | |
EE200000152A (et) | Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon | |
ATE380867T1 (de) | Lactoferrinrezeptorgen von moraxella | |
EP1012603A4 (en) | FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND METHODS OF USE | |
AU6745287A (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
HUP9900750A2 (hu) | Gén kifejezésére szolgáló promóterek | |
DK0805204T3 (da) | Bitestikel - specifikt receptorprotein og anvendelse heraf | |
RU94043698A (ru) | СПОСОБ ПОЛУЧЕНИЯ ФЕРМЕНТА ДЕСТАБИЛАЗЫ, ОБЛАДАЮЩЕГО ФИБРИНОЛИТИЧЕСКОЙ, ТРОМБОЛИТИЧЕСКОЙ, ЭНДО- И ЭКЗО- Е( -glu)-Lys-ИЗОПЕПТИДАЗНОЙ И АМИДОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ | |
TR200002611T2 (tr) | Beta-lipotropin ve kullanımları | |
AU6252294A (en) | A mutant protein and methods and materials for making and using it | |
AU2001251410A1 (en) | 12303, a novel human twik molecule and uses thereof | |
RU94046405A (ru) | Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок | |
PT870050E (pt) | Virus que expressam proteinas toxicas e linhas de celulas produtoras | |
WO2001046412A3 (de) | Interaktionsprotein für stat transkriptionsfaktor | |
MX9700255A (es) | Metodo para identificar acidos nucleicos que codifican las proteinas activadoras del promotor c-fos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EG | Technical examination (opinion): publication of technical examination (opinion) | ||
TC | Change of name | ||
B25A | Requested transfer of rights approved |
Owner name: GENCELL S.A. (FR) Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A. |
|
B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: GENCELL S.A. (FR) Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO NO 030279/RJ, DE 31/05/04, QUEIRA APRESENTAR DOCUMENTO DEALTERACAO DE NOME. |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: GENCELL S.A. (FR) Free format text: REFERENTE A RPI 1856 COD. (25.6) DE 01/08/2006, POR TER SIDO INDEVIDO. |
|
B25D | Requested change of name of applicant approved |
Owner name: GENCELL SAS (FR) Free format text: ALTERADO DE: GENCELL S.A. |
|
B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: DESCONHECIDA A PETICAO NO 003630/SP DE 01/03/2005, POR FALTA DE FUNDAMENTACAO LEGAL. |
|
B25D | Requested change of name of applicant approved |
Owner name: CENTELION S.A.S. (FR) Free format text: ALTERADO DE: GENCELL S.A.S. |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/10/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI-52400.68486/2013 ORIGEM: JUIZO DA 25A VARA FEDERAL DE SAO PAULO PROCESSO NO 0017574-93.2013.4.03.6100 ACAO DE NULIDADE DE PATENTE AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER SAS, CENTELION E CENTELION S.A., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MERCK SERONO S.A. E SAMJIN PHARMACEUTICAL CO. LTD. |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: INPI-52400.068486/2013 SECAO JUDICIARIA DE SAO PAULO - 25A VARA FEDERAL CIVEL DE SAO PAULO PROCESSO NO0017574-93.2013.403.6100 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER SAS, CENTELION, CENTELION S.A, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MERCK SERONO S.A E SAMJIN PHARMACEUTICAL CO. LTDA DECISAO: JULGO PROCEDENTE O PEDIDO FORMULADO PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9607583-0, PI 9610511-9, PI 9707889-1 E PI 9604907-3 E DETERMINO A RETIFICACAO DOS RESPECTIVOS PRAZOS DE VIGENCIA DE MODO A OBSERVAR A O DISPOSTO NO PARAGRAFO UNICO DO ARTIGO 229 DA LEI NO 9.279-96, EM INTERPRETACAO CONJUNTA COM O CAPUT DO ARTIGO 40 DO MESMO DIPLOMA. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2076 DE 19/10/2010, QUANTO AO PRAZO DE VALIDADE POR DETERMINACAO DA 25A VARA CIVEL FEDERAL DE SAO PAULO, PROC. 0017574-93.2013.403.6100 - ACAO ORDINARIA - INPI 52400.068486/2013-05. |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: INPI NO 52400.009771/2015-48 PROCESSO JUDICIAL: 0017574-93.2013.4.03.6100 NUP: 00848.000050/2015-10 (REF. 0017574-93.2013.4.03.6100) PARECER DE FORCA EXECUTORIA N. 00012/2020/EEFIN NAP/EEFINSP/PGF/AGU INTERESSADOS: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E OUTROS DECISAO: O JUIZO DA 25A VARA CIVEL FEDERAL DE SAO PAULO JULGOU O PEDIDO PARCIALMENTE PROCEDENTE, PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9607583-0, PI 9610511-9, E PI 9707889-1, ADEQUANDO AS PATENTES AOS ARTIGOS 229, P. U., E 40, CAPUT, DA LEI N. 9.279-96. ESTA DECISAO FOI POSTERIORMENTE CONFIRMADA PELO TRF DA 3A REGIAO, COM TRANSITO EM JULGADO EM 23 DE JULHO DE 2019. |